LifeMD’s Strategic Positioning and Financial Health Reinforce Buy Rating Despite Revenue Miss
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Yi Chen reiterated a Buy rating for LifeMD (LFMD) stock, despite a slight miss in Q3 revenue projections. LifeMD showed year-over-year growth in telehealth revenue and an increase in active subscribers. The company divested its majority ownership in WorkSimpli, enhancing its focus on telehealth and pharmacy. LifeMD's financial health is strong, with a solid cash position and no long-term debt. Chen set a 12-month price target of $9 for LFMD.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments